We sit down with Chris Major to reflect on the successes of 2019 and what is in store for Purolite Life Sciences in 2020.
As 2019 comes to an end, making way for the beginning of a new decade, we sat down with Global Sales & Marketing Director of Purolite’s Agarose Division, Chris Major, to reflect on the achievements of the past 12 months and discuss what the future holds for Praesto® agarose chromatography resins in 2020.
2019 has been a year of growth for our Praesto® line, with noticeable surges in order intake and manufacturing volume output. Our Protein A resin sales, specifically, have seen impressive growth when compared to 2018, accounting for 70% of total sales revenue. In October, we were delighted to announce that our Praesto® resin technology achieved FDA-approved implementation into commercial manufacturing processes. This is testament to our technology leadership, providing customers with shorter lead times, fair pricing and a commitment to strengthening global security of supply. Praesto® resins are now being used by two of the top ten global CMOs and eight of the world’s largest biopharmaceutical developers.
We have always been a global leader in resin innovation, and we will continue to invest strongly into R&D efforts throughout 2020 to achieve new levels of purification performance. In recent years, Purolite has invested over $150 million into a global expansion program. As part of this effort we are in the process of doubling the production capacity of our unique, uniform-bead jetting technology to provide 20,000L volume per annum. We will also continue our efforts in ensuring security of supply within the biopharmaceutical industry. Our partnership with Repligen Corporation is also integral to our continuous growth and product development. We look forward to this continued collaboration, with exciting times ahead.
Jetting technology is a solvent free process that produces uniform-size agarose beads with a narrow particle-size distribution. This eliminates the need for sieving, which is a necessary step in the manufacture of competitor resins to remove fine particles from the finished product. This cuts our manufacturing time in half. We combine the uniform beads with a new, high-performance Protein A ligand, from Repligen, NGL-Impact A™. No other supplier can supply uniform particle sized agarose beads, which gives our customers advantages in packing, capacity and shorter lead times.
Today, we’re proud to say that we have over 170 ongoing pre-clinical to Phase III projects in the pipeline. The demand from customers for ion exchange and protein A for their process scale-ups has been exponential. We’re expecting our Praesto® Jetted A50 resin to reach commercial FDA-approved manufacturing processes in Q1 2020 so are eager to see how this will continue to shape the industry in 2020.
I’d like to take this opportunity to thank all our customers and business partners for their continued support this year. I’d also like to acknowledge our Purolite family for their enthusiasm and hard work. Thank you for making 2019 a truly memorable year.
I wish you all the best for the holidays, and a wonderful start to 2020.